

In The Claims:

Please amend the claims as follows:

27. (Amended) An isolated human spasmolytic polypeptide having an amino acid sequence according to SEQ ID NO:1

Sub D3
Glu Lys Pro Ser Pro Cys Gln Cys Ser Arg Leu Ser Pro His Asn Arg Thr Asn Cys Gly Phe Pro Gly Ile Thr Ser Asp Gln Cys Phe Asp Asn Gly Cys Cys Phe Asp Ser Ser Val Thr Gly Val Pro Trp Cys Phe His Pro Leu Pro Lys Gln Glu Ser Asp Gln Cys Val Met Glu Val Ser Asp Arg Arg Asn Cys Gly Tyr Pro Gly Ile Ser Pro Glu Glu Cys Ala Ser Arg Lys Cys Cys Phe Ser Asn Phe Ile Phe Glu Val Pro Trp Cys Phe Phe Pro Asn Ser Val Glu Asp Cys His Tyr

or a homologue thereof comprising at least six disulphide bonds that form two trefoil domains, wherein said polypeptide is characterized by being in N-glycosylated form and having spasmolytic activity.

28. (Amended) The polypeptide of claim 27 wherein said polypeptide is glycosylated at an Asn present at position 15 of the amino acid sequence of said polypeptide.

29. (Amended) The polypeptide of claim 27, wherein the glycosylated form comprises a glycosylated side chain comprising at least one hexose unit.

30. (Amended) The polypeptide of claim 29, wherein the glycosylated side chain comprises at least one mannose unit.

31. (Amended) The polypeptide of claim 30, wherein the glycosylated side chain comprises 13-17 mannose units.

32. (Amended) The polypeptide of claim 27, wherein the glycosylated form comprises at least one unit of N-acetyl glucosamine (GlcNAc).

33. (Amended) The polypeptide of claim 27, wherein the glycosylated form comprises (GlcNAc)₂(Man)₁₀₋₁₅.